Traditional biobanks do not have enough relevant primary tumor tissue and are therefore restrictive in sharing with research groups. This results in a critical bottleneck for research and developing new diagnoses and treatment options.

Organoids is based on a breakthrough technology where patient-derived tumor tissue is expanded into DNA-stable cultures identical to the primary tumor tissue, even after multiple passages. The research material is therefore reproducible, and more accessible at a lower cost, thus allowing more research in ovarian cancer.

Other cancer types have large organoid banks, but not ovarian cancer. We wish to build this together with a comprehensive database of information per culture. The initiative will be non-profit. To obtain access to the biobank, each research group must agree to report all their research information back into the database, so the models continuously become more data-rich for the next research project.